Denali Therapeutics Inc. Profile Avatar - Palmy Investing

Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…

Biotechnology
US, South San Francisco [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Denali Therapeutics Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
0.0 IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
YoY Trends
  • No trends presentable at the moment.

Spending By Type

Awards
Obligations
Contracts IDV Contracts Grants Loans Direct Other

Denali Therapeutics Inc. can't present spending by time.

End of DNLI's Analysis
CIK: 1714899 CUSIP: 24823R105 ISIN: US24823R1059 LEI: - UEI: -
Secondary Listings
DNLI has no secondary listings inside our databases.